Back to search

Article

A Novel Bispecific Antibody Targeting Frizzled7 and PD-L1 Reverses Immunotherapy Resistance in Non-Small Cell Lung Cancer by Reprogramming the Tumor Microenvironment

2026-04-29

Abstract excerpt

<title>Abstract</title> <p> Immunotherapy efficacy in non-small cell lung cancer (NSCLC) remains limited, largely due to aberrant activation of the Wnt/β-Catenin pathway. However, the precise role of its receptor Frizzled7 (Fzd7) in immune checkpoint inhibitor (ICI)-resistance remains unexplored. Here, we elucidate the role of Fzd7 in shaping the immunosuppressive tumor microenvironment (TME) and develop a novel...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
61eadd3f-7d7e-5172-b691-bdb1bfd95812
DOI
10.21203/rs.3.rs-9337927/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Novel Bispecific Antibody Targeting Frizzled7 and PD-L1 Reverses Immunotherapy Resistance in Non-Small Cell Lung Cancer by Reprogramming the Tumor MicroenvironmentDOI 10.21203/rs.3.rs-9337927/v1
Select a neighboring publication to make it the new centre.